During the “Healthspan and Longevity” panel, Dr. Moody spoke among experts to answer the question “Can we live healthier, longer lives through biotechnology?” The panel agreed that there is consensus among the scientific community for the 7 hallmarks of aging, and companies are actively pursuing therapeutic interventions to address all 7 hallmarks.
The race is on for pharmaceutical companies to develop drugs for aging.
Dr. Moody stated that while there is consensus about the hallmarks of aging, the field of aging must mature. He cited a current lack of regulatory framework — framework which must be established for bona fide anti-aging drugs to obtain regulatory approval. The field of aging, Dr. Moody stated, needs consensus about this framework between think tanks, regulatory agencies, consortia, and companies in the space.
However, Dr. Moody noted, that as the field of aging matures, consensus among the community will follow.
He also noted the difference between academic research and pharmaceutical development. Dr. Moody commented that input from experienced drug developers is crucial to prepare academic proof-of-concept molecules for use in humans.